Risk-benefit assessment of methotrexate in the treatment of severe psoriasis

American Journal of Clinical Dermatology

Volumn 1, Issue 1, 2000, Pages 27-39

  Kuijpers, Astrid L A ^a   Van De Kerkhof, Peter C M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; METHOTREXATE;

HOSPITALIZATION; HUMAN; PSORIASIS; REVIEW; RISK ASSESSMENT;

HUMANS; IMMUNOSUPPRESSIVE AGENTS; METHOTREXATE; PSORIASIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX;

EID: 0033762048     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200001010-00003     Document Type: Review

References (122)

1. van de Kerkhof PCM. Methotrexate. In: Mier PD, van de Kerkhof PCM, editors. Textbook of psoriasis. Edinburgh: Churchill Livingstone, 1986; 233-51
2. Roenigk Jr HH, Maibach HI. Methotrexate. In: Roenigk HH, Maibach HI, editors. Psoriasis. 2nd ed. New York: Marcel Dekker, 1991; 563-75
3. Weinstein GD. Commentary: three decades of folic acid antagonists in dermatology. Arch Dermatol 1983; 119: 525-7
4. Gubner R. Effect of aminopterin on epithelial tissues. Arch Dermatol Syphilol 1951; 64: 688-99
5. Edmundson WF, Guy WB. Treatment of psoriasis with folic acid antagonists. Arch Dermatol 1958; 78: 200-3
6. Weinstein GD, Frost P. Methotrexate for psoriasis. A new therapeutic schedule. Arch Dermatol 1971; 103: 33-8
7. Ashton RE, Millward Sadler GH, White JE. Complications in methotrexate treatment of psoriasis with particular reference to liver fibrosis. J Invest Dermatol 1982; 79: 229-32
8. van de Kerkhof PC, Hoefnagels WH, van Haelst UJ, et al. Methotrexate maintenance therapy and liver damage in psoriasis. Clin Exp Dermatol 1985; 10: 194-200
9. Zachariae H, Kragballe K, Sogaard H. Methotrexate induced liver cirrhosis. Studies including serial liver biopsies during continued treatment. Br J Dermatol 1980; 102: 407-12
10. Nyfors A. Liver biopsies from psoriatics related to methotrexate therapy. Findings in post-methotrexate liver biopsies from 160 psoriatics. Acta Pathol Microbiol Scand A 1977; 85: 511-8
11. Jackson RC. Biological effects of folic acid antagonists with antineoplastic activity. Pharmacol Ther 1984; 25: 61-82
12. Burkhart CG. Treatment of psoriasis with methotrexate and folinic acid [letter]. J Am Acad Dermatol 1980; 3: 207-8
13. Ive FA, De Saram CF. Methotrexate and the citrovorum factor in the treatment of psoriasis. Trans St Johns Hosp Dermatol Soc 1970; 56: 45-7
14. Kremer JM. Methotrexate update. Scand J Rheumatol 1996; 25: 341-4
15. Rothenberg RJ, Graziano FM, Grandone JT, et al. The use of methotrexate in steroid-resistant systemic lupus erythematosus. Arthritis Rheum 1988; 31: 612-5
16. van den Hoogen FH, Boerbooms AM, Swaak AJ, et al. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol 1996; 35: 364-72
17. Kozarek RA, Patterson DJ, Gelfand MD, et al. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease [see comments]. Ann Intern Med 1989; 110: 353-6
18. Mullarkey MF. Methotrexate and asthma [see comments]. J Allergy Clin Immunol 1991; 88: 272-4
19. Schwartz PM, Barnett SK, Atillasoy ES, et al. Methotrexate induces differentiation of human keratinocytes. Proc Natl Acad Sci U S A 1992; 89: 594-8
20. Lammers AM, van de Kerkhof PC, Mier PD. Reduction of leukotriene B4-induced intraepidermal accumulation of polymorphonuclear leukocytes by methotrexate in psoriasis. Br J Dermatol 1987; 116: 667-71
21. Ternowitz T, Bjerring P, Andersen PH, et al. Methotrexate inhibits the human C5a-induced skin response in patients with psoriasis. J Invest Dermatol 1987; 89: 192-6
22. Cronstein BN. Molecular therapeutics. Methotrexate and its mechanism of action. Arthritis Rheum 1996; 39: 1951-60
23. Jeffes EW, McCullough JL, Pittelkow MR, et al. Methotrexate therapy of psoriasis: differential sensitivity of proliferating lymphoid and epithelial cells to the cytotoxic and growth-inhibitory effects of methotrexate. J Invest Dermatol 1995; 104: 183-8
24. Weinstein GD, Jeffes E, McCullough JL. Cytotoxic and immunologic effects of methotrexate in psoriasis. J Invest Dermatol 1990; 95: 49S-52S
25. Chang DM, Baptiste P, Schur PH. The effect of antirheumatic drugs on interleukin 1 (IL-1) activity and IL-1 and IL-1 inhibitor production by human monocytes. J Rheumatol 1990; 17: 1148-57
26. Segal R, Mozes E, Yaron M, et al. The effects of methotrexate on the production and activity of interleukin-1. Arthritis Rheum 1989; 32: 370-7
27. McCullough JL, Snyder D, Weinstein GD. Factors affecting human percutaneous penetration of methotrexate and its analogues in vitro. J Invest Dermatol 1976; 67: 26-30
28. Bjerring P, Beck HI, Zachariae H, et al. Topical treatment of psoriatic skin with methotrexate cream: a clinical, pharmacokinetic, and histological study. Acta Derm Venereol 1986; 66: 515-9
29. Said S, Jeffes EWB, Weinstein GD. Systemic treatment; methotrexate. Clin Dermatol 1997; 15: 781-97
30. Kamel RS, al Hakiem MH, Rademaker M, et al. Pharmacokinetics of small doses of methotrexate in patients with psoriasis. Acta Derm Venereol 1988; 68: 267-70
31. Wan SH, Huffman DH, Azarnoff DL, et al. Pharmacokinetics of 1-beta-D-arabinofuranosylcytosine in humans. Cancer Res 1974; 34: 392-7
32. Jones SK, Aherne GW, Campbell MJ, et al. Methotrexate pharmacokinetics in psoriatic patients developing hepatic fibrosis. Arch Dermatol 1986; 122: 666-9
33. Hendel L, Hendel J, Johnsen A, et al. Intestinal function and methotrexate absorption in psoriatic patients. Clin Exp Dermatol 1982; 7: 491-7
34. Pinkerton CR, Welshman SG, Glasgow JF, et al. Can food influence the absorption of methotrexate in children with acute lymphoblastic leukaemia? Lancet 1980; 2: 944-6
35. Bleyer WA. The clinical pharmacology of methotrexate: new applications of an old drug. Cancer 1978; 41: 36-51
36. Tung JP, Maibach HI. The practical use of methotrexate in psoriasis. Drugs 1990; 40: 697-712
37. Taylor JR, Halprin KM. Effect of sodium salicylate and indomethacin on methotrexate-serum albumin binding. Arch Dermatol 1977; 113: 588-91
38. Hendel J. Clinical pharmacokinetics of methotrexate in psoriasis therapy. Dan Med Bull 1985; 32: 329-37
39. Hendel J, Nyfors A. Nonlinear renal elimination kinetics of methotrexate due to saturation of renal tubular reabsorption. Eur J Clin Pharmacol 1984; 26: 121-4
40. Lawrence JR, Steele WH, Stuart JF, et al. Dose dependent methotrexate elimination following bolus intravenous injection. Eur J Clin Pharmacol 1980; 17: 371-4
41. Nierenberg DW, Mamelok RD. Toxic reaction to methotrexate in a patient receiving penicillin and furosemide: a possible interaction [letter]. Arch Dermatol 1983; 119: 449-50
42. Singh RR, Malaviya AN, Pandey JN, et al. Fatal interaction between methotrexate and naproxen [letter]. Lancet 1986; 1: 1390
43. Maiche AG. Acute renal failure due to concomitant action of methotrexate and indomethacin [letter]. Lancet 1986; 1: 1390
44. Thomas DR, Dover JS, Camp RD. Pancytopenia induced by the interaction between methotrexate and trimethoprim-sulfamethoxazole [letter]. J Am Acad Dermatol 1987; 17: 1055-6
45. Thomas MH, Gutterman LA. Methotrexate toxicity in a patient receiving trimethoprim-sulfamethoxazole. J Rheumatol 1986; 13: 440-1
46. Groenendal H, Rampen FH. Methotrexate and trimethoprim-sulphamethoxazole - a potentially hazardous combination [see comments]. Clin Exp Dermatol 1990; 15: 358-60
47. Larsen FG, Nielsen Kudsk F, Jakobsen P, et al. Interaction of etretinate with methotrexate pharmacokinetics in psoriatic patients. J Clin Pharmacol 1990; 30: 802-7
48. Evans WE, Christensen ML. Drug interactions with methotrexate. J Rheumatol 1985; 12: 15-20
49. Steele WH, Stuart JF, Lawrence JR, et al. Enhancement of methotrexate absorption by subdivision of dose. Cancer Chemother Pharmacol 1979; 3: 235-7
50. Roenigk Jr HH, Auerbach R, Maibach HI, et al. Methotrexate in psoriasis: revised guidelines. J Am Acad Dermatol 1988; 19: 145-56
51. Collins P, Rogers S. The efficacy of methotrexate in psoriasis - a review of 40 cases. Clin Exp Dermatol 1992; 17: 257-60
52. Kumar B, Dhar S, Handa S, Kaur I. Methotrexate in childhood psoriasis. Pediatr Dermatol 1994; 11: 271-3
53. van Dooren Greebe RJ, Kuijpers ALA, Mulder J, et al. Methotrexate revisited: effects of long-term treatment in psoriasis. Br J Dermatol 1994; 130: 204-10
54. Baker H. Methotrexate the conservative treatment for psoriasis. In: Farber EM, Cox AJ, editors. Psoriasis: Proceedings of the second international symposium. New York: Yorke Medical Books, 1976; 235-42
55. Ellis CN, Fradin MS, Hamilton TA. Duration of remission during maintenance cyclosporin therapy for psoriasis: relationship to maintenance dose and degree of improvement during initial therapy. Arch Dermatol 1995; 131: 791-5
56. Fradin MS, Ellis CN, Voorhees JJ. Efficacy of cyclospporin a in psoriasis: a summary of the United States' experience. Br J Dermatol 1990; 122: 21-5
57. Nyfors A. Benefits and adverse drug experiences during long-term methotrexate treatment of 248 psoriatics. Dan Med Bull 1978; 25: 208-11
58. Zachariae H, Zachariae E. Methotrexate treatment of psoriatic arthritis. Acta Derm Venereol 1987; 67: 270-3
59. Black R, O'Brien W, Van Scott E, et al. Methotrexate therapy in psoriatic arthritis. JAMA 1964; 189: 743-7
60. Weinblatt ME, Coblyn JS, Fox DA, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985; 312: 818-22
61. Gollnick H. Acitretin in psoriasis: an update. In: Saurat J, editor. Retinoids 10 years on. Basel: Karger, 1991; 204-13
62. Duhra P. Treatment of gastrointestinal symptoms associated with methotrexate therapy for psoriasis. J Am Acad Dermatol 1993; 28: 466-9
63. Zonneveld IM, Bakker WK, Dijkstra PF, et al. Methotrexate osteopathy in long-term, low-dose methotrexate treatment for psoriasis and rheumatoid arthritis. Arch Dermatol 1996; 132: 184-7
64. Kettunen R, Huikuri HV, Oikarinen A, et al. Methotrexate-linked ventricular arrhythmias. Acta Derm Venereol 1995; 75: 391-2
65. Duhra P, Foulds IS. Methotrexate-induced impairment of taste acuity. Clin Exp Dermatol 1988; 13: 126-7
66. Pearce HP, Wilson BB. Erosion of psoriatic plaques: an early sign of methotrexate toxicity. J Am Acad Dermatol 1996; 35: 835-8
67. Hausknecht RU. Methotrexate and misoprostol to terminate early pregnancy. N Engl J Med 1995; 333: 537-40
68. Roenigk Jr HH, Auerbach R, Maibach H, et al. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol 1998; 38: 478-85
69. Morris LF, Harrod MJ, Menter MA, et al. Methotrexate and reproduction in men: case report and recommendations. J Am Acad Dermatol 1993; 29: 913-6
70. Zachariae H. Methotrexate side-effects [see comments]. Br J Dermatol 1990; 122 Suppl. 36:
71. Hendel J, Nyfors A. Impact of methotrexate therapy on the folate status of psoriatic patients. Clin Exp Dermatol 1985; 10: 30-5
72. Weinblatt ME, Fraser P. Elevated mean corpuscular volume as a predictor of hematologic toxicity due to methotrexate therapy. Arthritis Rheum 1989; 32: 1592-6
73. Morgan SL, Baggott JE, Vaughn WH, et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial [see comments]. Ann Intern Med 1994; 121: 833-41
74. Stern RS, Zierler S, Parrish JA. Methotrexate used for psoriasis and the risk of noncutaneous or cutaneous malignancy. Cancer 1982; 50: 869-72
75. Nyfors A, Jensen H. Frequency of malignant neoplasms in 248 long-term methotrexate-treated psoriatics. A preliminary study. Dermatologica 1983; 167: 260-1
76. Benedict WF, Baker MS, Haroun L, et al. Mutagenicity of cancer chemotherapeutic agents in the Salmonella/microsome test. Cancer Res 1977; 37: 2209-13
77. Boffa MJ, Chalmers RJ, Haboubi NY, et al. Sequential liver biopsies during long-term methotrexate treatment for psoriasis: a reappraisal. Br J Dermatol 1995; 133: 774-8
78. Kamen BA, Nylen PA, Camitta BM, et al. Methotrexate accumulation and folate depletion in cells as a possible mechanism of chronic toxicity to the drug. Br J Haematol 1981; 49: 355-60
79. Barak AJ, Tuma DJ, Beckenhauer HC. Methotrexate hepatotoxicity. J Am Coll Nutr 1984; 3: 93-6
80. Nyfors A, Poulsen H. Liver biopsies from psoriatics related to methotrexate therapy. 2. Findings before and after methotexate therapy in 88 patients. A blind study. Acta Pathol Microbiol Scand A 1976; 84: 262-70
81. Roenigk Jr HH, Auerbach R, Bergfeld WF. A cooperative prospective study of the effects of chemotherapy of psoriasis on liver biopsies. In: Farber EM, Cox AJ, editors. Psoriasis: Proceedings of the second international symposium. New York: Yorke Medical Books, 1976; 243-8
82. Mitchell D, Smith A, Rowan B, et al. Serum type III procollagen peptide, dynamic liver function tests and hepatic fibrosis in psoriatic patients receiving methotrexate. Br J Dermatol 1990; 122: 1-7
83. Zachariae H, Grunnet E, Sogaard H. Liver biopsy in methotrexate-treated psoriatics-a re-evalution. Acta Derm Venereol 1975; 55: 291-6
84. Robinson JK, Baughman RD, Auerbach R, et al. Methotrexate hepatotoxicity in psoriasis. Consideration of liver biopsies at regular intervals. Arch Dermatol 1980; 116: 413-5
85. Paul BS, Momtaz K, Stern RS, et al. Combined methotrexate - ultraviolet B therapy in the treatment of psoriasis. J Am Acad Dermatol 1982; 7: 758-62
86. Newman M, Auerbach R, Feiner H, et al. The role of liver biopsies in psoriatic patients receiving long-term methotrexate treatment. Improvement in liver abnormalities after cessation of treatment. Arch Dermatol 1989; 125: 1218-24
87. Reese LT, Grisham JW, Aach RD, et al. Effects of methotrexate on the liver in psoriasis. J Invest Dermatol 1974; 62: 597-602
88. Zachariae H, Sogaard H. Methotrexate-induced liver cirrhosis. A follow-up. Dermatologica 1987; 175: 178-82
89. Zachariae H, Sogaard H, Heickendorff L. Methotrexate-induced liver cirrhosis. Clinical, histological and serological studies - a further 10-year follow-up. Dermatology 1996; 192: 343-6
90. Gilbert SC, Klintmalm G, Menter A, et al. Methotrexate-induced cirrhosis requiring liver transplantation in three patients with psoriasis. A word of caution in light of the expanding use of this 'steroid-sparing' agent [see comments]. Arch Intern Med 1990; 150: 889-91
91. Creswell SN, Burrows D. Liver biopsies in psoriatics - complications and evaluation. Int J Dermatol 1980; 19: 217-9
92. Sherlock S, Dick R, Van Leeuwen DJ. Liver biopsy today. The Royal Free Hospital experience. J Hepatol 1985; 1: 75-85
93. McGill DB, Rakela J, Zinsmeister AR, et al. A 21-year experience with major hemorrhage after percutaneous liver biopsy [see comments]. Gastroenterology 1990; 99: 1396-400
94. Rademaker M, Webb JA, Lowe DG, et al. Magnetic resonance imaging as a screening procedure for methotrexate induced liver damage. Br J Dermatol 1987; 117: 311-6
95. Saverymuttu SH, Joseph AE, Maxwell JD. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J Clin Res Ed 1986; 292: 13-5
96. Verschuur AC, van Everdingen JJ, Cohen EB, et al. Liver biopsy versus ultrasound in methotrexate-treated psoriasis: a decision analysis. Int J Dermatol 1992; 31: 404-9
97. Mitchell D, Johnson RJ, Testa HJ, et al. Ultrasound and radionuclide scans - poor indicators of liver damage in patients treated with methotrexate. Clin Exp Dermatol 1987; 12: 243-5
98. Paramsothy J, Strange R, Sharif H, et al. The use of antipyrine clearance to measure liver damage in psoriatic patients receiving methotrexate. Br J Dermatol 1988; 119: 761-5
99. Hendel J, Poulsen H, Nyfors B, et al. Changes in liver histology during methotrexate therapy of psoriasis correlated to the concentration of methotrexate and folate in erythrocytes. Acta Pharmacol Toxicol Copenh 1985; 56: 321-6
100. McHenry PM, Bingham EA, Callender ME, et al. Dynamic hepatic scintigraphy in the screening of psoriatic patients for methotrexate-induced hepatotoxicity. Br J Dermatol 1992; 127: 122-5
101. Ferguson WR, Laird JD, Cranly K. Early dynamic studies as an adjunct to liver scintigraphy in the investigation of diffuse liver disease. J Nucl Med 1981; 22: 88
102. van Dooren Greebe RJ, Kuijpers ALA, Buijs WC, et al. The value of dynamic hepatic scintigraphy and serum aminoterminal propeptide of type III procollagen for early detection of methotrexate-induced hepatic damage in psoriasis patients. Br J Dermatol 1996; 134: 481-7
103. Zachariae H, Sogaard H, Heickendorff L. Serum aminoterminal propeptide of type III procollagen. A non-invasive test for liver fibrogenesis in methotrexate-treated psoriatics. Acta Derm Venereol 1989; 69: 241-4
104. Zachariae H, Aslam HM, Bjerring P, et al. Serum aminoterminal propeptide of type III procollagen in psoriasis and psoriatic arthritis: relation to liver fibrosis and arthritis [see comments]. J Am Acad Dermatol 1991; 25: 50-3
105. Risteli J, Sogaard H, Oikarinen A, et al. Aminoterminal propeptide of type III procollagen in methotrexate-induced liver fibrosis and cirrhosis. Br J Dermatol 1988; 119: 321-5
106. Prockop DJ, Kivirikko KI, Tuderman L, et al. The biosynthesis of collagen and its disorders (1st of 2 pts). N Engl J Med 1979; 1301: 13-23
107. Risteli J, Niemi S, Trivedi P, et al. Rapid equilibrium radioimmunoassay for the amino-terminal propeptide of human type III procollagen. Clin Chem 1988; 34: 715-8
108. Frei A, Zimmermann A, Weigand K. The N-terminal propeptide of collagen type III in serum reflects activity and degree of fibrosis in patients with chronic liver disease. Hepatology 1984; 4: 830-4
109. Horslev Petersen K, Saxne T, Haar D, et al. The aminoterminal-type-III procollagen peptide and proteoglycans in serum and synovial fluid of patients with rheumatoid arthritis or reactive arthritis. Rheumatol Int 1988; 8: 1-9
110. Zachariae H, Halkier Sorensen L, Heickendorff L. Serum aminoterminal propeptide of type III procollagen in progressive systemic sclerosis and localized scleroderma. Acta Derm Venereol 1989; 69: 66-70
111. McLaren MI, Fleming JS, Walmsley BH, et al. Dynamic liver scanning in cirrhosis. Br J Surg 1985; 72: 394-6
112. Kanzler MH, Gorsulowsky D. Serum aminoterminal propeptide of type III procollagen in psoriasis and psoriatic arthritis: relation to liver fibrosis [letter; comment]. J Am Acad Dermatol 1992; 26: 509
113. Boffa MJ, Smith A, Chalmers RJ, et al. Serum type III procollagen aminopeptide for assessing liver damage in methotrexate-treated psoriatic patients. Br J Dermatol 1996; 135: 538-44
114. Oogarah PK, Rowland PI, Mitchell DM, et al. Abnormalities of serum type III procollagen aminoterminal peptide in methotrexate-treated psoriatic patients with normal liver histology do not correlate with hepatic ultrastructural changes. Br J Dermatol 1995; 133: 512-8
115. Boffa MJ, Chalmers RJ. Methotrexate for psoriasis. Clin Exp Dermatol 1996; 21: 399-408
116. Themido R, Loureiro M, Pecegueiro M, et al. Methotrexate hepatotoxicity in psoriatic patients submitted to long-term therapy. Acta Derm Venereol 1992; 72: 361-4
117. Greaves MW, Weinstein GD. Treatment of psoriasis [see comments]. N Engl J Med 1995; 332: 581-8
118. Adams JD. Concurrent methotrexate and etretinate therapy for psoriasis [letter]. Arch Dermatol 1983; 119: 793
119. Beck HI, Foged EK. Toxic hepatitis due to combination therapy with methotrexate and etretinate in psoriasis. Dermatologica 1983; 167: 94-6
120. Jeffes EW, III, Weinstein GD. Methotrexate and other chemotherapeutic agents used to treat psoriasis. Dermatol Clin 1995; 13: 875-90
121. Weinstein GD, White GM. An approach to the treatment of moderate to severe psoriasis with rotational therapy. J Am Acad Dermatol 1993; 28: 454-9
122. van Dooren Greebe RJ, Kuijpers ALA, Termorshuizen F, et al. Interruption of long-term methotrexate treatment in psoriasis. Evaluation of clinical course and laboratory parameters after discontinuation and reintroduction of weekly oral methotrexate. Acta Derm Venereol 1995; 75: 393-6